CN115066428A - 硼酸衍生物 - Google Patents

硼酸衍生物 Download PDF

Info

Publication number
CN115066428A
CN115066428A CN202180010057.8A CN202180010057A CN115066428A CN 115066428 A CN115066428 A CN 115066428A CN 202180010057 A CN202180010057 A CN 202180010057A CN 115066428 A CN115066428 A CN 115066428A
Authority
CN
China
Prior art keywords
alkyl
acid
benzofuran
dichloromethane
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180010057.8A
Other languages
English (en)
Inventor
王业柳
刘琦超
商现星
陈昌俊
张权浩
杨斌
陈曦
孙颖慧
李红娟
郭慧萍
朱岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN115066428A publication Critical patent/CN115066428A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

式(I)所示的硼酸衍生物或其药学上可接受的盐、溶剂化物、多晶型物或异构体，包含这些化合物的药物组合物，以及此类化合物在治疗跟lmp7相关的疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180010057.8A 2020-01-19 2021-01-19 硼酸衍生物 Pending CN115066428A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020100582173 2020-01-19
CN202010058217.3A CN113135944A (zh) 2020-01-19 2020-01-19 硼酸衍生物
PCT/CN2021/072667 WO2021143924A1 (zh) 2020-01-19 2021-01-19 硼酸衍生物

Publications (1)

Publication Number Publication Date
CN115066428A true CN115066428A (zh) 2022-09-16

Family

ID=76808717

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010058217.3A Pending CN113135944A (zh) 2020-01-19 2020-01-19 硼酸衍生物
CN202180010057.8A Pending CN115066428A (zh) 2020-01-19 2021-01-19 硼酸衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010058217.3A Pending CN113135944A (zh) 2020-01-19 2020-01-19 硼酸衍生物

Country Status (2)

Country Link
CN (2) CN113135944A (zh)
WO (1) WO2021143924A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537383A (ja) * 2021-10-14 2024-10-10 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド ボロン酸誘導体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861324A (zh) * 2007-11-13 2010-10-13 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CN104321060A (zh) * 2011-12-22 2015-01-28 阿雷斯贸易股份有限公司 α-氨基硼酸衍生物,选择性免疫蛋白酶体抑制剂
CN107001391A (zh) * 2014-10-01 2017-08-01 默克专利股份公司 硼酸衍生物
CN107001390A (zh) * 2014-10-01 2017-08-01 默克专利股份公司 硼酸衍生物
CN107074885A (zh) * 2014-10-01 2017-08-18 默克专利股份公司 硼酸衍生物
CN107108660A (zh) * 2014-10-01 2017-08-29 默克专利股份公司 硼酸衍生物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861324A (zh) * 2007-11-13 2010-10-13 诺瓦提斯国际药物有限公司 β-内酰胺酶抑制剂
WO2013056163A1 (en) * 2011-10-14 2013-04-18 The Regents Of The University Of California Beta-lactamase inhibitors
CN104321060A (zh) * 2011-12-22 2015-01-28 阿雷斯贸易股份有限公司 α-氨基硼酸衍生物,选择性免疫蛋白酶体抑制剂
CN107001391A (zh) * 2014-10-01 2017-08-01 默克专利股份公司 硼酸衍生物
CN107001390A (zh) * 2014-10-01 2017-08-01 默克专利股份公司 硼酸衍生物
CN107074885A (zh) * 2014-10-01 2017-08-18 默克专利股份公司 硼酸衍生物
CN107108660A (zh) * 2014-10-01 2017-08-29 默克专利股份公司 硼酸衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EIDAM, OLIV ET AL: "Design, Synthesis, Crystal Structures, and Antimicrobial Activity of Sulfonamide Boronic Acids as β-Lactamase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 21, 31 December 2010 (2010-12-31), pages 7852 - 7863, XP055259885, DOI: 10.1021/jm101015z *

Also Published As

Publication number Publication date
CN113135944A (zh) 2021-07-20
WO2021143924A1 (zh) 2021-07-22

Similar Documents

Publication Publication Date Title
CN108017603B (zh) 三环化合物及其用途
EP3483142A1 (en) Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
JP7511557B2 (ja) ブロモドメインタンパク質阻害薬としてのイミノスルホン化合物、医薬組成物及びその医薬用途
KR20100103702A (ko) 축합 아미노디하이드로 티아진 유도체
WO2011060321A1 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
TW202227433A (zh) 中環或大環之經苄基取代的雜環衍生物及相關用途
CN113993859B (zh) 杂环化合物、其制备方法及其使用方法
JP2024512428A (ja) 抗ウイルス化合物
CA3178470A1 (en) Modulators of alpha-1 antitrypsin
JP7050054B2 (ja) Ｐｄｅ４阻害剤としての縮合環系化合物
CN115066428A (zh) 硼酸衍生物
CN112020494A (zh) 用作tlr2信号转导调节剂的化合物
EP2914582A2 (en) Chiral fluorinating reagents
SU1266472A3 (ru) Способ получени /1-имидазолил-карбонил/-7-/3-(3-пиридил)-1 @ ,3 @ -пиррол-/1,2- @ /-тиазола
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
TW201722938A (zh) 作為電位閘控鈉通道調節子之磺醯胺化合物
TW201938517A (zh) 苯並雜環化合物及其用途
CN115151553A (zh) 硼酸衍生物
CN114907389A (zh) 硼酸衍生物
KR960012371B1 (ko) 신규 5-메톡시 알킬 암모늄 테트라히드로푸란 및 테트라히드로티오펜
CN111094300B (zh) 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
JP2001106673A (ja) ビアリールウレア誘導体
TW202227398A (zh) Stat抑制性化合物及組合物
KR20240089564A (ko) Shp2 억제제, 이를 포함하는 약학적 조성물 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination